Do food patterns matter?
People reporting more dietary spermidine had lower mortality in a long-running cohort.
A favorable association
Healthy diet and lifestyle may contribute. No supplement was assigned. [1]
SPERMIDINE · ORAL SUPPLEMENT RESEARCH
Spermidine.
A closer look at
healthy aging.
A natural compound in food and our cells, spermidine has caught scientists’ attention for its role in cellular maintenance. Human research offers intriguing dietary and early biomarker findings. The bigger memory trial brings an important reality check.
Explore the findingsIngredient research, not proof of longer life, increased cellular recycling or results from a finished Neurogan product.
01 / WHAT THE RESEARCH ASKS
Three questions. Different kinds of evidence.
Spermidine is a polyamine, a small molecule involved in normal cell processes. It comes from diet, production in the body and gut microbes. [4]
Does memory improve?
An early pilot suggested a benefit. SmartAge did not confirm an advantage on its primary memory test.
Promising start, null follow-up
Both used plant extracts, not today’s high-dose retail capsules. [2] [3]
What changes in the body?
New studies track blood chemistry and proteins linked to cell maintenance, with mixed results.
Clues, not clinical outcomes
Blood markers do not show how quickly cells recycle material or whether people live longer. [4] [5] [6]
02 / THE DIETARY FINDING
A long-term link worth exploring.
In 829 adults followed from 1995 to 2015, greater dietary spermidine intake was associated with lower mortality. This chart shows adjusted estimates, not a supplement effect. [1]
Estimated mortality over 20 years
Adjusted for age, sex and caloric intake. Each bar starts at zero; scale ends at 50%.
What the dietary study can and cannot tell us
The Bruneck cohort used repeated, dietitian-administered food-frequency questionnaires. There were 341 deaths during follow-up. A more extensively adjusted model reported a mortality hazard ratio of 0.76 (95% CI 0.67–0.86) per standard-deviation higher spermidine intake. This is a different analysis from the three adjusted bars above.
The association was also evaluated in an independent cohort. Still, measurement error, remaining confounding and the wider dietary pattern can affect the findings. The study does not prescribe a supplement dose or demonstrate extra years of life from a capsule. Read the primary abstract [1]
03 / THE MEMORY REALITY CHECK
An early signal.
A bigger test.
The 2018 pilot made spermidine worth investigating. The 2022 SmartAge trial tested 100 older adults for 12 months and found no significant advantage on its primary memory outcome. [2] [3]
Both trials enrolled people who noticed memory decline but did not have dementia. These are not trials proving dementia prevention or treatment.
No confirmed memory advantage
Difference in memory-score change
−0.03
95% CI −0.11 to +0.05 · P = .47
Why the pilot does not outweigh SmartAge
The 30-person pilot’s end-of-treatment contrast favored the extract: 0.17 (95% CI −0.01 to 0.35). Its standardized effect size was Cohen’s d = 0.77, with a wide interval of 0 to 1.53. The uncertainty included no effect. Within-group improvement alone is not proof of a treatment advantage. [2]
SmartAge used an intention-to-treat primary analysis and did not show significant benefit on that outcome or its main secondary outcomes. Exploratory verbal-memory and inflammation findings were not significant after correction for multiple testing; an exploratory executive-function finding also went in an unfavorable direction. A hypothesis about higher doses is not evidence that higher doses work. [3]
04 / CELLULAR MAINTENANCE
What does “autophagy” really mean?
Autophagy is the process cells use to break down and recycle their own components. A protein linked to that process is not a direct measurement of how much recycling is happening. [4] [6]
01
A biological reason
Laboratory research links spermidine with cell-maintenance pathways.
02
A human clue
A rice-extract pilot reported changes in autophagy-related proteins.
03
A question still open
Do supplements improve cellular recycling and meaningful health outcomes?
Conceptual evidence diagram, not a proven chain of effects or a time-to-benefit chart. The rice-extract study did not measure lifespan or establish increased autophagic flux, the rate of cellular recycling.
| Measured marker | Reported change | Interpretation |
|---|---|---|
| Beclin-1 | +7.3% | Autophagy-related protein, not measured cellular recycling |
| ULK1 | +13.4% | Another autophagy-related protein |
| BDNF | +12.1% | A signaling protein, not improved memory |
| hs-CRP | −20.8% | An inflammation marker, not disease prevention |
| VLDL / triglycerides | −20.1% / −26.9% | Blood lipids, not reduced cardiovascular events |
Very early evidence: 12 people across two active-dose groups, no placebo group described. These are within-group changes, not confirmed differences versus control. The accessible abstract gives no p-values or confidence intervals. [6]
05 / INSIDE THE HUMAN STUDIES
The details behind each finding.
Open each study for dose, duration, methods and limitations. These are selected studies, not a complete systematic review.
Food intake and long-term survival
Finding: Higher reported spermidine intake was associated with lower mortality, including after adjustment for several potential confounders. [1]
Population, exposure, methods and limitations
- Population
- 829 adults aged 45–84; 49.9% male
- Exposure
- Usual dietary spermidine; no assigned supplement
- Duration
- 1995–2015; 20-year follow-up
- Design
- Prospective population-based observational study
Methods: 2,540 dietary assessments using validated food-frequency questionnaires in 1995, 2000, 2005 and 2010. All-cause mortality was the outcome; 341 participants died during follow-up. The fully adjusted hazard ratio was 0.76 (95% CI 0.67–0.86) per standard-deviation higher intake.
Limits: Neither food intake nor supplement use was randomized. The abstract does not give an actionable supplement dose. Its comparison with a younger age is a risk analogy, not measured years of life gained. Source access: primary abstract.
A small, encouraging memory signal
Finding: The estimated memory benefit favored the plant extract, but was imprecise. The between-group confidence interval included zero. [2]
Population, dose, methods, results and safety
- Population
- 30 cognitively intact adults, aged 60–80, with subjective cognitive decline
- Dose / formula
- Reported 1.2 mg spermidine/day in spermidine-rich wheat-germ extract [7]
- Duration
- 3 months
- Design
- Randomized, double-blind, placebo-controlled phase 2a pilot
Methods: A behavioral mnemonic similarity task was assessed at baseline and after treatment. The authors emphasized effect-size estimates. This was an extract containing other compounds, not isolated spermidine trihydrochloride.
Results: End-of-intervention contrast mean 0.17 (95% CI −0.01 to 0.35); Cohen’s d = 0.77 (95% CI 0 to 1.53). This does not mean a 77% memory improvement. A small pilot with wide intervals needs independent confirmation.
Safety and dose source: The companion safety publication reports 1.2 mg/day and no between-group differences in vital signs, weight, clinical chemistry, hematology or self-reported health after treatment. It is the same pilot cohort, not an additional independent clinical trial. No inference about long-term high-dose safety is warranted. Source access: primary abstracts for the memory and safety reports. [7]
The larger trial did not confirm the benefit
Finding: No significant primary memory benefit over 12 months. Main secondary outcomes were also not significantly improved. [3]
Population, extract amount, active dose and full results
- Population
- 100 older adults with subjective cognitive decline; eligibility 60–90 years; mean age 69; 49 women
- Dose / formula
- 750 mg/day wheat-germ extract supplying about 0.9 mg spermidine, 0.5 mg spermine and 0.2 mg putrescine
- Duration / allocation
- 12 months; 51 extract, 49 placebo; 89 completed intervention
- Design
- Single-center, randomized, double-masked, placebo-controlled phase 2b trial
Methods: Six 125 mg capsules per day; comparator was 750 mg microcrystalline cellulose. The primary endpoint was change in mnemonic discrimination on the Mnemonic Similarity Task. Intention-to-treat analysis used imputation for missing data; comparisons adjusted for age, sex and baseline outcome.
Results: Between-group difference −0.03 (95% CI −0.11 to 0.05), P = .47. Mean adherence was 95.3%. No significant changes were observed in main secondary outcomes. Exploratory results did not survive correction for multiple testing and cannot establish benefit.
Safety and limits: Adverse events were balanced. This supports tolerability of this low-active-dose extract over the studied period, not years of concentrated synthetic use. A selected older population, one center and the extract composition limit generalization. 750 mg extract is not 750 mg spermidine. The pilot’s 1.2 mg and SmartAge’s 0.9 mg are the respective publication-reported amounts, not a randomized dose comparison. Source access: primary full text.
More intake did not mean more plasma spermidine
Finding: Plasma spermine increased, but plasma spermidine and putrescine did not significantly increase. Salivary polyamines were also unchanged. [4]
Population, formulation, schedule and measurement details
- Population
- 12 healthy adults; 8 women and 4 men; eligible ages 18–45
- Dose / formula
- 15 mg spermidine/day from Chlorella algae powder and soybean extract
- Duration
- Two 5-day periods separated by a 9-day washout
- Design
- Randomized, triple-blinded, placebo-controlled crossover
Methods: Each participant received both treatments. Capsules supplied 1.5 mg spermidine each; five capsules formed a 7.5 mg dose, given twice daily. Blood and saliva were sampled repeatedly, with polyamines measured by liquid chromatography–tandem mass spectrometry. Plasma metabolomics used nuclear magnetic resonance.
Results: The pattern suggested conversion of spermidine to spermine before systemic circulation, but did not directly trace that conversion. Measured metabolomic comparisons did not establish broad metabolic benefit.
Limits: A small, five-day exposure per treatment cannot assess cognition or longevity. Plasma is not whole blood, and an unchanged plasma concentration does not prove absence of tissue effects. It also does not prove autophagy. The trihydrochloride mentioned among laboratory reagents was not the administered supplement. Source access: primary full text.
Reassuring short-term tolerability in older men
Finding: No product-related adverse events and no significant between-treatment changes in measured clinical or laboratory safety parameters were reported. [5]
Population, reported dose, endpoints and boundaries
- Population
- 37 healthy men aged 50–70; BMI 18.5–28
- Dose / formula
- Reported 40 mg/day high-purity spermidine trihydrochloride (hpSPD)
- Duration
- 7-day and up-to-28-day dosing periods
- Design
- Exploratory randomized, double-blind, within-subject, placebo-controlled trial
Results: No significant changes in clinical, lipid, chemistry or hematological safety parameters versus placebo. Serum and urine polyamine concentrations showed no substantial changes. Compliance was high.
Limits: The abstract does not resolve whether the stated 40 mg describes free-base equivalent or salt mass, so it cannot be confidently dose-matched to retail labels. No numerical clinical benefit or lifespan endpoint is reported. This is short-term evidence in healthy men, not a general high-dose safety guarantee.
Commercial context: Two authors were Chrysea Labs employees; other authors reported funding from Chrysea Labs. Source access: primary abstract, not independently verified full-text tables.
New markers, still an early question
Finding: The 3.3 mg rice-extract group had favorable baseline changes in several blood markers. These are exploratory clues without a placebo comparison. [6]
Population, dose, marker changes and uncertainty
- Population
- 12 healthy men and women; mean age 54.5 ± 7.9 years
- Dose / formula
- 1.5 or 3.3 mg spermidine/day from Miricell rice-germ extract
- Duration
- 56 days / 8 weeks
- Design
- Randomized, single-blinded, parallel-group pilot with two active doses
Methods: Measurements at weeks 0 and 8 included vitals, diet records, compliance and blood markers. Outcomes included Beclin-1, ULK1, BDNF, homocysteine, hs-CRP and a lipid panel.
Results: The abstract reports changes from baseline at 3.3 mg/day: Beclin-1 +7.3%, ULK1 +13.4%, BDNF +12.1%, hs-CRP −20.8%, VLDL −20.1% and triglycerides −26.9%. It describes a good safety profile but gives no adverse-event counts.
Limits: No placebo group is described. No p-values, confidence intervals or numerical between-dose comparison are supplied in the accessible abstract. These proteins are not a direct autophagic-flux measurement, and BDNF is not a memory test. The result cannot be transferred from this rice extract to a different formulation.
Commercial context: One author is Chief Scientific Officer of Nutraland USA, the supplier named for the extract. Source access: primary abstract; publisher full text could not be retrieved.
06 / FROM RESEARCH TO A LABEL
Same name. Not always the same dose.
Food extracts contain more than spermidine. Concentrated supplements may use spermidine trihydrochloride, a salt form. Its total mass is not interchangeable with the mass of spermidine alone.
Extract is not active dose
SmartAge’s 750 mg of wheat-germ extract supplied about 0.9 mg of spermidine. The rest was other extract material. [3]
Read the full ingredient name
“10 mg trihydrochloride” and “10 mg spermidine, as trihydrochloride” may use different labeling conventions. Check the Supplement Facts and batch assay before comparing.
Liposomal is a separate question
Adding a phospholipid carrier does not itself prove better human absorption, increased cellular recycling or better outcomes.
| Product | What the listing says | How it relates to the studies |
|---|---|---|
| Spermidine Tablets ↗ | 10 mg spermidine trihydrochloride per tablet. Suggested use: two tablets daily, totaling 20 mg salt mass. | Not the low-active-dose wheat extract tested for memory. Do not equate these milligrams with active spermidine from food extracts. |
| Spermidine Pro Capsules ↗ | 50 mg spermidine “as spermidine trihydrochloride” per capsule/serving; one capsule daily. | The “as” wording differs from explicit salt-mass labeling. Confirm the assay basis before comparing with the 40 mg hpSPD study. More is not proven better. |
| Liposomal Spermidine Capsules ↗ | 20 mg per capsule; one daily. Ingredients include spermidine trihydrochloride and sunflower lecithin. The comparison section describes 20 mg trihydrochloride. | Confirm the current label’s active-versus-salt basis. The cited trials do not establish absorption superiority or efficacy for this liposomal product. |
| Spermidine Drops ↗ | 20 mg spermidine trihydrochloride per 0.5 mL. Two 0.5 mL servings daily total 40 mg salt mass. Listing displayed sold out when checked. | A liquid is not the tested plant extract. Matching a printed “40 mg” does not establish equivalence to hpSPD, and swallowed trials do not validate under-the-tongue delivery. |
Listings checked September 9, 2026. Formulas, labels and availability can change. The figures above reproduce manufacturer descriptions, not an independent potency assay. No exact Neurogan product trial was identified in the selected publications.
What should I check before comparing products?
Look for the amount per serving, servings per day, exact chemical form, whether the amount is active spermidine or salt mass, and a batch-matched certificate of analysis. Compare source materials and allergens as well as milligrams. A purity test does not show a clinical benefit.
There is no proven best daily dose for memory, longevity or cellular recycling in this evidence set. Study protocols are not personal dosing advice, and taking more cannot be assumed to overcome a null trial result.
07 / SAFETY & OPEN QUESTIONS
Encouraging tolerability.
Not unlimited reassurance.
What the trials observed
SmartAge reported balanced adverse events with a low-dose wheat-germ extract over 12 months. The 40 mg hpSPD trial found no product-related adverse events over up to 28 days in healthy older men. The rice-extract pilot described favorable short-term safety measures. [3] [5] [6]
Small trials may miss rare harms. A year of low-dose extract is not a year of high-dose salt, and none of these studies establishes safety of indefinite use.
Where extra care is sensible
These trials do not establish safety during pregnancy or breastfeeding, in children, or with serious medical conditions. Medication interactions and long-term cancer-related outcomes remain insufficiently characterized.
Check wheat, soy and other formulation ingredients if you have allergies. Discuss supplementation with a qualified clinician if you take prescription medicines, have an active medical condition or are receiving cancer treatment. This is a precaution about limited evidence, not a claim that spermidine causes cancer.
Does spermidine supplementation extend human lifespan?
Not established. Dietary cohorts find associations, while the supplementation studies here measured memory, blood markers or short-term safety. None demonstrates longer human life from a spermidine supplement.
Does a change in blood proteins prove autophagy improved?
No. Protein levels can change without telling us the rate at which cells break down and recycle material. The rice-germ pilot provides preliminary biomarker data, not confirmed whole-body autophagy or better health. [6]
Does unchanged blood spermidine mean it was not absorbed?
Not necessarily. Metabolism, tissue uptake and tightly regulated concentrations complicate interpretation. The 2023 trial found an increase in plasma spermine, a related molecule. That observation is not proof of a clinically useful effect, either. [4]
THE TAKEAWAY
Interesting biology.
Keep the human results in view.
Spermidine deserves thoughtful research. The dietary association is encouraging, newer biomarker work is emerging, and the best-known memory trial was null. A useful next step is stronger, longer trials of clearly defined formulations.
Follow the evidence ↓08 / SOURCES & FURTHER READING
Read what each finding rests on.
This focused oral research guide separates observational food intake from assigned supplements. Six selected studies are discussed; the seventh reference is a companion safety report from the memory pilot, not a separate participant group. Primary abstracts are labeled where full text was not verified. Product listings are linked separately above.
- PRIMARY ABSTRACT / OBSERVATIONAL
Higher spermidine intake is linked to lower mortality: a prospective population-based study
Kiechl et al. American Journal of Clinical Nutrition, 2018. DOI: 10.1093/ajcn/nqy102. PMID: 29955838.
Read primary abstract ↗ - PRIMARY ABSTRACT / MEMORY PILOT
The effect of spermidine on memory performance in older adults at risk for dementia: a randomized controlled trial
Wirth et al. Cortex, 2018. DOI: 10.1016/j.cortex.2018.09.014. PMID: 30388439. Dose and safety cross-checked with reference 7.
Read primary abstract ↗ - PRIMARY FULL TEXT / SMARTAGE
Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline
Schwarz et al. JAMA Network Open, 2022. DOI: 10.1001/jamanetworkopen.2022.13875. PMID: 35616942. Registry: NCT03094546.
Read full study ↗ - PRIMARY FULL TEXT / PHARMACOKINETICS
High-dose spermidine supplementation does not increase spermidine levels in blood plasma and saliva of healthy adults
Senekowitsch et al. Nutrients, 2023. DOI: 10.3390/nu15081852. PMID: 37111071.
Read full study ↗ - PRIMARY ABSTRACT / SAFETY
Supplementation of spermidine at 40 mg/day has minimal effects on circulating polyamines
Keohane et al. Nutrition Research, 2024. DOI: 10.1016/j.nutres.2024.09.012. PMID: 39405978. Registry: NCT05459961.
Read primary abstract ↗ - PRIMARY ABSTRACT / RICE-GERM PILOT
Effects of spermidine-rich rice germ extract supplement on biomarkers of healthy aging and autophagy: proof-of-concept pilot study
Bruno, La Monica & Ziegenfuss. Alternative Therapies in Health and Medicine, 2025;31(6):9–13. PMID: 40862848. Publisher full text could not be retrieved; no unreported statistical significance is assumed.
Read primary abstract ↗ - PRIMARY ABSTRACT / COMPANION SAFETY REPORT
Safety and tolerability of spermidine supplementation in mice and older adults with subjective cognitive decline
Schwarz et al. Aging, 2018. DOI: 10.18632/aging.101354. PMID: 29315079. The human component is the pilot cohort discussed in reference 2. Animal findings are not counted as human safety evidence.
Read primary abstract ↗